For customized products, please discuss further
These effects are generally not a reason to stop therapy
The findings, which have yet to be published, showed that Tirzepatide reduced participants risk of heart failure outcomes (hospitalization, death, and the need to increase medication dosage) by 38 percent compared with those taking placebo
American Journal of Respiratory and Critical Care Medicine Foer D, Strasser ZH, Cui J, Cahill KN, Boyce JA, Murphy SN et al (2023) Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes
It may mitigate oxidative stress, preserving vascular integrity and function